Scarica l'app Stockscreener
23.59
1.46%
-0.35
Dopo l'orario di chiusura:
23.60
0.01
+0.04%
Precedente Chiudi:
$23.94
Aprire:
$23.22
Volume 24 ore:
359.46K
Relative Volume:
2.39
Capitalizzazione di mercato:
$792.29M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-6.98%
1M Prestazione:
-3.16%
6M Prestazione:
+27.17%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.22
$24.57
Intervallo di 1 settimana:
$22.30
$25.94
Portata 52W:
$14.35
$30.99
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $36.00 at HC Wainwright - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - Defense World
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com Canada
ArriVent BioPharma stock target raised on positive trial results By Investing.com - Investing.com Canada
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com UK
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - MarketBeat
Should investors be concerned about ArriVent BioPharma Inc. (AVBP)? - US Post News
Analyst boosts ArriVent BioPharma shares price target after promising trial data - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - MarketBeat
ArriVent reports promising data on lung cancer drug firmonertinib - Investing.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - ForexTV.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib - The Bakersfield Californian
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - StockTitan
ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher - MarketBeat
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance
ArriVent, lung cancer drug developer, files for $100M IPO - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4% - MarketBeat
ArriVent BioPharma Inc. Inc. (AVBP) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month High at $26.24 - MarketBeat
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - Quantisnow
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet - Yahoo Finance
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - Yahoo Canada Finance
Oppenheimer Reiterates Outperform Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
H.C. Wainwright ups ArriVent BioPharma shares target on clinical trial catalysts - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $30.00 at HC Wainwright - MarketBeat
HC Wainwright Boosts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $30.00 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Issues Quarterly Earnings Results - Defense World
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Given Outperform Rating at Oppenheimer - MarketBeat
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - wallstreet:online
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - Defense World
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - MarketBeat
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - StockTitan
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer - MyChesCo
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - StockTitan
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Non sono disponibili dati finanziari per Arrivent Biopharma Inc (AVBP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):